Rami Moucari

Summary

Publications

  1. doi request reprint Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B
    Rami Moucari
    Hepatology Department and INSERM U773, Beaujon Hospital, Clichy, France
    Liver Int 31:122-8. 2011
  2. doi request reprint Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
    Rami Moucari
    Service d Hépatologie et INSERM U773 CRB3, Hopital Beaujon, Clichy, France
    Gut 59:1694-8. 2010
  3. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
  4. doi request reprint Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antivir Ther 14:1183-8. 2009
  5. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
  6. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
  7. ncbi request reprint Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
  8. doi request reprint Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Antivir Ther 17:61-70. 2012
  9. doi request reprint Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy F 92110, France
    Gastroenterology 134:416-23. 2008
  10. doi request reprint High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009

Detail Information

Publications21

  1. doi request reprint Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B
    Rami Moucari
    Hepatology Department and INSERM U773, Beaujon Hospital, Clichy, France
    Liver Int 31:122-8. 2011
    ..Both HBV markers provide complementary information on the status of HBV infection. However, the relevance of serum HBsAg levels and its use as a reliable replacement for both covalently closed circular DNA and HBV DNA remain unclear...
  2. doi request reprint Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
    Rami Moucari
    Service d Hépatologie et INSERM U773 CRB3, Hopital Beaujon, Clichy, France
    Gut 59:1694-8. 2010
    ..The aim of this study was to evaluate the short-term effect of an HCV protease inhibitor monotherapy on IR in parallel with an antiviral effect...
  3. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
    ..We assessed the influence of combination therapy on the risk of HCC, liver-related complications (ascites, variceal bleeding), and liver-related death (or liver transplantation)...
  4. doi request reprint Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antivir Ther 14:1183-8. 2009
    ....
  5. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  6. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
    ..Viral eradication in chronic hepatitis C patients with sustained virological response (SVR) after interferon (IFN) therapy remains controversial...
  7. ncbi request reprint Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
    ....
  8. doi request reprint Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Antivir Ther 17:61-70. 2012
    ..The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of HBV genomes directly isolated from patients' sera...
  9. doi request reprint Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy F 92110, France
    Gastroenterology 134:416-23. 2008
    ..Our study was designed to test the association between insulin resistance (IR) and hepatitis C virus (HCV) genotypes, serum HCV RNA level and liver fibrosis stage in a large prospective cohort of chronic hepatitis C (CHC) patients...
  10. doi request reprint High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009
    ..To assess the HBsAg seroconversion rate and its impact on the long-term outcome in chronic hepatitis B patients treated with conventional interferon, and to analyze the serum HBsAg concentration prior to seroconversion...
  11. doi request reprint Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
    Sarah Maylin
    Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterology 135:821-9. 2008
    ..It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR)...
  12. ncbi request reprint Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study
    Pierre Bedossa
    Service d Anatomie Pathologique, CNRS UMR 8149, Clichy, France
    Hepatology 46:380-7. 2007
    ..In multivariate analysis, triglyceride and HDL cholesterol were predictors of NASH in patients with genotype 1, whereas in patients with genotype 3, AST was the only predictor...
  13. ncbi request reprint Interferon therapy for chronic hepatitis B
    Tarik Asselah
    Service d Hepatologie, INSERM U773, CRB3, University of Paris VII, Hopital Beaujon, 92110 Clichy, France
    Clin Liver Dis 11:839-49, viii. 2007
    ..This article summarizes the results obtained with interferon alfa and pegylated interferon alfa, as monotherapy and in combination with lamivudine, in the treatment of chronic hepatitis B...
  14. doi request reprint Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome
    Pierre Emmanuel Rautou
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Hopital Beaujon, AP HP, Clichy, France
    Clin Gastroenterol Hepatol 7:1230-5. 2009
    ..An increased level of serum alanine aminotransferase (ALT) is an objective marker for acute liver injury. We analyzed the significance of changes in ALT levels in Budd-Chiari syndrome patients...
  15. ncbi request reprint Acute hepatitis E with severe jaundice: report of three cases
    Rami Moucari
    Hepatology Department and INSERM U773, CRB3, University of Paris VII, Beaujon Hospital, Clichy, France
    Eur J Gastroenterol Hepatol 19:1012-5. 2007
    ..HEV-RNA detection by real-time reverse transcriptase-PCR is a very efficacious diagnostic tool in anti-HEV immunoglobulin-M-negative cases...
  16. ncbi request reprint [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]
    Rami Moucari
    Pôle des Maladies de l Appareil Digestif, Service d Hépatologie et INSERM U773 CRB3, Universite Paris VII, Hopital Beaujon, Clichy
    Gastroenterol Clin Biol 31:643-54. 2007
    ..Insulin resistance and steatosis, appear to be associated with fibrosis progression and impairment of sustained response to antiviral treatment...
  17. doi request reprint Bleeding in patients with Budd-Chiari syndrome
    Pierre Emmanuel Rautou
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Hopital Beaujon, AP HP, Clichy, France
    J Hepatol 54:56-63. 2011
    ..This study aimed to assess the incidence, severity, and risk factors of major bleeding in patients with Budd-Chiari syndrome (BCS) receiving anticoagulation therapy...
  18. doi request reprint Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Liver Int 32:93-101. 2012
    ..To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir...
  19. doi request reprint Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management
    Pierre Emmanuel Rautou
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Hopital Beaujon, AP HP and INSERM U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris 7 Denis Diderot, Clichy, France
    Am J Gastroenterol 104:1140-6. 2009
    ..However, patient characteristics, causal factors, and treatment outcomes have changed since these indices have been elaborated. Validation in a recent patient population and comparison of predictive accuracy between these PIs are needed...
  20. ncbi request reprint High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy
    Rami Moucari
    Service d hépatologie and INSERM CRB3, Hopital Beaujon, AP HP, Universite Paris VII, Clichy, France
    J Hepatol 46:596-604. 2007
    ..To evaluate the efficacy of peginterferon alfa-2b and ribavirin in unselected consecutive patients with chronic hepatitis C, treated outside of trials, who were relapsers or non-responders to interferon and ribavirin combination...
  21. doi request reprint Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes
    Pierre Emmanuel Rautou
    Pôle des Maladies de l Appareil Digestif, Service d Hepatologie, Hopital Beaujon, AP HP and INSERM U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris 7 Denis Diderot, Clichy, France
    J Hepatol 51:47-54. 2009
    ..Budd-Chiari syndrome (BCS) mainly affects women of childbearing age. We aimed to clarify whether pregnancy, a thrombotic risk factor, should be contraindicated in patients with known and treated BCS...